UOC
PETX

UBS O'Connor’s Aratana Therapeutics, Inc. PETX Stock Holding History

UBS O'Connor’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,000
Closed -$535K – 890
2014
Q4 		$535K Sell
30,000
-218,589
-88% -$2.72M 0.01% 404
2014
Q3 		$2.5M Buy
248,589
+168,789
+212% +$2.05M 0.04% 282
2014
Q2 		$1.25M Buy
79,800
+64,263
+414% +$911K 0.01% 311
2014
Q1 		$288K Buy
+15,537
New +$311K 0.01% 387

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's PETX Position: Q1 2015 in Review

UBS O'Connor sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2015, closing a stake of 30,000 shares — an estimated $535K sold.

UBS O'Connor first reported a position in PETX in Q1 2014 and held it in 4 quarters. The position peaked at $2.5M in Q3 2014. 93 funds tracked by Wall St. Rank hold PETX as of Q1 2015.

  • UBS O'Connor reported no remaining Aratana Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • UBS O'Connor sold 30,000 Aratana Therapeutics, Inc. shares in Q1 2015, an estimated $535K.
  • UBS O'Connor first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • UBS O'Connor's Aratana Therapeutics, Inc. position peaked at $2.5M in Q3 2014.
  • 93 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2015.

Based on UBS O'Connor's 13F filing for Q1 2015, filed 14 May 2015.